Orgenesis Inc. Selling, General and Administrative Expense of Revenue

Selling, General and Administrative Expense of Revenue of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Selling, General and Administrative Expense of Revenue growth rates and interactive chart.


Highlights and Quick Summary

  • Selling, General and Administrative Expense of Revenue for the quarter ending June 29, 2021 was 27.8% (a -10.5% decrease compared to previous quarter)
  • Year-over-year quarterly Selling, General and Administrative Expense of Revenue decreased by -88.03%
  • Annual Selling, General and Administrative Expense of Revenue for 2020 was 243.32% (a 10.36% increase from previous year)
  • Annual Selling, General and Administrative Expense of Revenue for 2019 was 220.47% (a 152.28% increase from previous year)
  • Annual Selling, General and Administrative Expense of Revenue for 2018 was 87.39% (a 0.0% decrease from previous year)
  • Twelve month Selling, General and Administrative Expense of Revenue ending June 29, 2021 was 73.63% (a -38.98% decrease compared to previous quarter)
  • Twelve month trailing Selling, General and Administrative Expense of Revenue decreased by -66.87% year-over-year
Trailing Selling, General and Administrative Expense of Revenue for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
73.63% 120.67% 246.98% 222.22%
Visit stockrow.com/ORGS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Selling, General and Administrative Expense of Revenue of Orgenesis Inc.

Most recent Selling, General and Administrative Expense of Revenueof ORGS including historical data for past 10 years.

Interactive Chart of Selling, General and Administrative Expense of Revenue of Orgenesis Inc.

Orgenesis Inc. Selling, General and Administrative Expense of Revenue for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 27.8% 31.06%
2020 338.81% 232.27% 205.03% 187.33% 243.32%
2019 292.21% 195.78% 246.6% 712.65% 220.47%
2018 99.45% 64.33% 83.35% 126.86% 87.39%
2017 124.28% 105.83% 0.0% 122.62% 91.08%
2016 0.0% 69.17% 0.0% 191.96% 191.96% 97.55%
2015 135.68%
2014 0.0%
2013 0.0%
2012 0.0%
2011 0.0%

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.